Clinical Trial Results:
A Phase IIIb Study to Determine Efficacy and Safety of
Extended Drotrecogin Alfa (Activated) Therapy in
Patients With Persistent Requirement for Vasopressor
Support After 96-Hour Infusion With Commercial
Drotrecogin Alfa (Activated).
Summary
|
|
EudraCT number |
2004-001319-71 |
Trial protocol |
ES |
Global completion date |
08 May 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
03 Jan 2017
|
First version publication date |
03 Jan 2017
|
Other versions |
|
Summary report(s) |
EVBQ Approved CSR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.